Mikhail Blagosklonny is a well-renowned scientist who specializes in aging and cancer. At the Rosewell Park Cancer Institute, he works as an oncology professor. He is a holder of both Ph.D. in experimental medicine and cardiology as well as an M.D. in internal medicine at the First Pavlov State Medical University of St. Petersburg.
Blagosklonny’s career journey has been simply outstanding. This is because for each and every organization that he has worked with, he managed to make it successful in one way or another. In 2002, he was employed an associate professor at the New York Medical College before moving to Ordway Research Institute where he took the position of a scientist. He diligently served the institution for seven years until he was offered a position at the Roswell Park Cancer Institute where he still offers his services.
Read more on Impact Journals.
Mikhail Blagosklonny enjoys researching on cancer and its targeted therapies that protect the cells in our body from damage. Moreover, he is fascinated by the underlying mechanism of aging as well as anti-aging drugs. He formulated a hypothesis on the possible role of TOR signaling in cancer and aging and proposed that by using rapamycin for possible life extension. TOR is basically an evolutionarily conserved nutrient that senses the protein kinase which is responsible for regulating metabolism and growth in all eukaryotic cells. Blagosklonny is passionate about his longevity research and has a lot of hopes on rapamycin.
Mikhail Blagosklonny is the author of the aging hyperfunction theory. He has also written about chemotherapeutic engineering and cell cyclotherapy. He has over 300 research articles, reviews, book chapters that are all published under his name. Blagosklonny is also known to be an associate editor of the PLOS ON, the International Journal of Cancer, as well as the American Journal of Pathology. His hard work and determination are what have contributed to his success in becoming one of the most recognized oncologists in the world. He points out that he loves humanity and his vision to the world is to create a disease-free environment for people. He says that the fight against cancer will only be successful if we work hand-in-hand.
Read more about Mikhail at LinkedIn.com.
Clay Siegall has spent the bulk of his adult years in the field of biotechnology. Earning his Ph.D. in genetics from George Washington University and a B.S. in Zoology from the University of Maryland were just the beginning. Clay worked for the National Cancer Institute from 1988-1991 and Bristol-Myers Squibb Pharmaceutical Research Institute from 1991-1997, clearly laying the foundation for his work in cancer research. In 1997 he co-founded Seattle Genetics in Washington State and then used research, innovation, and drug development practices to enlarge the company. Seattle Genetics’ work has marked Seattle as a center for cancer research. Mr. Siegall’s twenty years of cancer research and therapeutic drug development does not just benefit his own company, he also is a board member of several pharmaceutical companies. He has authored seventy publications and has fifteen patents.
Seattle Genetics is currently doing seventy trials for their new Antibody-drug conjugate “Adcetris” and is considered a leader in developing antibody-drugs. This type of drug sends cancer fighting cells to the source of the disease. The current trials are being conducted for results in various types of lymphoma. Adcetris is only one of thirteen drugs that are part of Siegall’s “ambitious plans” for the industry. In their own words, Seattle Genetics is a “biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer.” (http://www.seattlegenetics.com/about). A noble intention as most cancer fighting drugs can damage healthy cells as well as the radical ones. The new Antibody-drug lines target only the cancer cells and leave the other vital healthy ones alone. Adcetris is already commercially available in sixty-five countries fighting against the life stealing disease of cancer.
According to cancer.org “Approximately 39.0 percent of men and women will be diagnosed with cancer of any site at some point during their lifetime.” With the side effects and complications of most conventional cancer drugs, this work by Clay Siegall and Seattle Genetics is a giant step in the eradication this horrible disease. Their fight against this malady that knows no boundaries, one that attacks young and old, rich and poor, is a fight for us all.